| 0 (0%) | 09-27 14:26 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 23.34 | 1-year : | 23.81 |
| Resists | First : | 19.98 | Second : | 20.38 |
| Pivot price | 19.4 | |||
| Supports | First : | 19.34 | Second : | 16.09 |
| MAs | MA(5) : | 19.4 | MA(20) : | 19.4 |
| MA(100) : | 19.4 | MA(250) : | 19.45  |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 6.6 | D(3) : | 6.6 |
| RSI | RSI(14): 38.7 | |||
| 52-week | High : | 21.97 | Low : | 16.19 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ PBCT ] has closed Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 20.44 - 20.54 | 20.54 - 20.62 |
| Low: | 19.07 - 19.2 | 19.2 - 19.31 |
| Close: | 19.23 - 19.43 | 19.43 - 19.59 |
Sat, 08 Apr 2023
Proton boron capture therapy (PBCT) induces cell death and mitophagy in a heterotopic glioblastoma model - Nature
Tue, 08 Mar 2022
M&T Bank (MTB) & People's United (PBCT) Announce Merger Date - Nasdaq
Wed, 29 Sep 2021
Treatment with Cisplatin-Based Chemotherapy Yields High Risk of Mortality Unrelated to Disease in Testicular Cancer - CancerNetwork
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 428 (M) |
| Shares Float | 419 (M) |
| Held by Insiders | 0.9 (%) |
| Held by Institutions | 75 (%) |
| Shares Short | 15,670 (K) |
| Shares Short P.Month | 10,290 (K) |
| EPS | 0.69 |
| EPS Est Next Qtrly | 0.27 |
| EPS Est This Year | 0.93 |
| EPS Est Next Year | 1.13 |
| Book Value (p.s.) | 17.84 |
| Profit Margin | 31.1 % |
| Operating Margin | 42.3 % |
| Return on Assets (ttm) | 0.9 % |
| Return on Equity (ttm) | 7.8 % |
| Qtrly Rev. Growth | -14.4 % |
| Gross Profit (p.s.) | 4.53 |
| Sales Per Share | 4.53 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 27.72 |
| PEG Ratio | 1.2 |
| Price to Book value | 1.08 |
| Price to Sales | 4.28 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | 2021-11-14 |
| Ex-Dividend Date | 2021-10-28 |
|
|
|
|
|
|
|
|
|